Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene - PubMed (original) (raw)
. 1997 May 15;158(10):4584-90.
Affiliations
- PMID: 9144470
Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene
B Gerstmayer et al. J Immunol. 1997.
Abstract
T cells require at least two signals for activation and clonal expansion. The first signal conferring specificity is initiated by interaction of the T cell receptor with antigenic peptides in the context of MHC molecules. The second, costimulatory signal can be provided by cell surface molecules on APCs such as B7-1 (CD80) and B7-2 (CD86), which interact with their counter-receptors on T cells. The absence of costimulatory signals presents one possible mechanism for tumor cells to escape immune surveillance. In experimental models transfection of B7 genes into tumor cells can result in T cell-dependent tumor rejection. We have developed a novel approach to direct the costimulatory B7-2 molecule to the surface of target cells. Our approach is based on a chimeric fusion protein that consists of the extracellular domain of human B7-2 fused to a single-chain Ab domain (scFv) specific for the ErbB2 protein, a type I growth factor receptor overexpressed in a high percentage of human adenocarcinomas. This B7-2(225)-scFv(FRP5) molecule expressed in the yeast Pichia pastoris and purified from culture supernatants is functionally active and binds to B7 counter-receptors and to ErbB2. B7-2(225)-scFv(FRP5) localizes specifically to the surface of ErbB2-expressing target cells, thereby providing a costimulatory signal that results in enhanced proliferation of syngeneic T cells. Our results suggest that effective tumor vaccines for cancer immunotherapy could be created by targeting such chimeric ligands to the surface of tumor cells.
Similar articles
- A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M, Weth R, Wels WS. Biburger M, et al. J Mol Biol. 2005 Mar 11;346(5):1299-311. doi: 10.1016/j.jmb.2004.12.052. Epub 2005 Jan 22. J Mol Biol. 2005. PMID: 15713482 - Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein.
Gerstmayer B, Hoffmann M, Altenschmidt U, Wels W. Gerstmayer B, et al. Cancer Immunol Immunother. 1997 Nov-Dec;45(3-4):156-8. doi: 10.1007/s002620050421. Cancer Immunol Immunother. 1997. PMID: 9435862 Free PMC article. - Costimulation and its role in organ transplantation.
Bluestone JA. Bluestone JA. Clin Transplant. 1996 Feb;10(1 Pt 2):104-9. Clin Transplant. 1996. PMID: 8680045 Review. - The role of B7 costimulation in T-cell immunity.
Harris NL, Ronchese F. Harris NL, et al. Immunol Cell Biol. 1999 Aug;77(4):304-11. doi: 10.1046/j.1440-1711.1999.00835.x. Immunol Cell Biol. 1999. PMID: 10457196 Review.
Cited by
- Generation and characterization of ErbB2-CAR-engineered cytokine-induced killer cells for the treatment of high-risk soft tissue sarcoma in children.
Merker M, Pfirrmann V, Oelsner S, Fulda S, Klingebiel T, Wels WS, Bader P, Rettinger E. Merker M, et al. Oncotarget. 2017 Aug 2;8(39):66137-66153. doi: 10.18632/oncotarget.19821. eCollection 2017 Sep 12. Oncotarget. 2017. PMID: 29029499 Free PMC article. - Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity.
Zhang C, Oberoi P, Oelsner S, Waldmann A, Lindner A, Tonn T, Wels WS. Zhang C, et al. Front Immunol. 2017 May 18;8:533. doi: 10.3389/fimmu.2017.00533. eCollection 2017. Front Immunol. 2017. PMID: 28572802 Free PMC article. - Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.
Ahmed N, Brawley VS, Hegde M, Robertson C, Ghazi A, Gerken C, Liu E, Dakhova O, Ashoori A, Corder A, Gray T, Wu MF, Liu H, Hicks J, Rainusso N, Dotti G, Mei Z, Grilley B, Gee A, Rooney CM, Brenner MK, Heslop HE, Wels WS, Wang LL, Anderson P, Gottschalk S. Ahmed N, et al. J Clin Oncol. 2015 May 20;33(15):1688-96. doi: 10.1200/JCO.2014.58.0225. Epub 2015 Mar 23. J Clin Oncol. 2015. PMID: 25800760 Free PMC article. Clinical Trial. - Selective inhibition of tumor growth by clonal NK cells expressing an ErbB2/HER2-specific chimeric antigen receptor.
Schönfeld K, Sahm C, Zhang C, Naundorf S, Brendel C, Odendahl M, Nowakowska P, Bönig H, Köhl U, Kloess S, Köhler S, Holtgreve-Grez H, Jauch A, Schmidt M, Schubert R, Kühlcke K, Seifried E, Klingemann HG, Rieger MA, Tonn T, Grez M, Wels WS. Schönfeld K, et al. Mol Ther. 2015 Feb;23(2):330-8. doi: 10.1038/mt.2014.219. Epub 2014 Nov 6. Mol Ther. 2015. PMID: 25373520 Free PMC article. - TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy.
Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, Corder A, Schönfeld K, Koch J, Dotti G, Heslop HE, Gottschalk S, Wels WS, Baker ML, Ahmed N. Grada Z, et al. Mol Ther Nucleic Acids. 2013 Jul 9;2(7):e105. doi: 10.1038/mtna.2013.32. Mol Ther Nucleic Acids. 2013. PMID: 23839099 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous